Last reviewed · How we verify
BMS-650032
BMS-650032 is a PD-1 inhibitor, which works by blocking the PD-1 receptor on T cells to enhance anti-tumor immune response.
BMS-650032 is a PD-1 inhibitor, which works by blocking the PD-1 receptor on T cells to enhance anti-tumor immune response. Used for Non-small cell lung cancer, PD-L1 positive.
At a glance
| Generic name | BMS-650032 |
|---|---|
| Also known as | Asunaprevir (ASV) |
| Sponsor | Bristol-Myers Squibb |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By blocking the PD-1 receptor, BMS-650032 allows T cells to recognize and attack cancer cells more effectively. This mechanism is similar to other PD-1 inhibitors, such as nivolumab and pembrolizumab, which have shown efficacy in various types of cancer.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
Common side effects
- Pneumonitis
- Hypothyroidism
- Hyperthyroidism
Key clinical trials
- Switching Regimen in Treating Cirrhotic HCV GT1b Subjects (PHASE2)
- Early Post-marketing Study of Daclatasvir (Daklinza®) + Asunaprevir (Sunvepra®) in the Treatment of Chronic Hepatitis C (CHC) in Adults
- Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio Therapy
- Postmarketing Surveillance of the Safety and Effectiveness of Daclatasvir and Asunaprevir for the Treatment of Chronic HCV Genotype 1B Infection in the Routine Clinical Practice in Korea
- Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C
- A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1 (PHASE3)
- Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual (PHASE3)
- Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BMS-650032 CI brief — competitive landscape report
- BMS-650032 updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI